English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

ulmonary arterial hypertension (PAH) is a life-threatening disease characterized by progressively elevated pulmonary vascular resistance. Sustained elevation of pulmonary vascular resistance causes severe right ventricular (RV) hypertrophy and failure accompanied by severely reduced cardiac output and leads to poor prognosis. Treatment with vasodilators, such as epoprostenol (prostaglandin I2), calcium channel blockers, endothelin receptor antagonists and phosphodiesterase type 5 inhibitor have been effective,1–3 but PAH is still a fatal disorder in many patients. A new and safe therapy for PAH is therefore needed. It is important not only to reduce the pulmonary vascular resistance but also to improve RV function.

Are Adrenergic Receptor Blockers Effective or Contraindicated in Pulmonary Arterial Hypertension?